The new drug class can kill brain cancer cells with mutations in the ACVR1 gene and shrink tumours in mice.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.